37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
4 citations
,
September 2024 in “BMC Cancer” 1 citations
,
January 2021 in “Open Access Journal of Cancer & Oncology” Energy healing treatment improved flutamide's solubility and stability, potentially enhancing its effectiveness for prostate cancer.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
November 2024 in “Advances in Pharmacology and Pharmacy” A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.
February 2026 in “Clinical and Experimental Dermatology” Bicalutamide improved hair growth more than spironolactone in women with hair loss.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
6 citations
,
September 2017 in “Multiple Sclerosis and Related Disorders” Nail loss may be a side effect of the MS drug teriflunomide.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
39 citations
,
January 2019 in “Journal of Dermatological Treatment” Ketoconazole cream is effective for skin conditions like seborrheic dermatitis and may help with hair loss and other skin issues, with generally mild side effects.
March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” Early diagnosis, genetic testing, and personalized care are essential for managing tuberous sclerosis.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
15 citations
,
May 1966 in “The Journal of Urology” A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
1 citations
,
January 2024 in “Dermatologic Therapy” Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.